] . 2014. “Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant To Hypomethylating Therapy Or Best Supportive Care In Patients Aged 50 To 75 With Intermediate-2 And High-Risk Myelodysplastic Syndrome: Blood And M”. Biol Blood Marrow Transplant 20 (10). Biol Blood Marrow Transplant: 1566-72. doi:10.1016/j.bbmt.2014.06.010.
. 2014. “Myelodysplastic Syndromes In The United States: An Update For Clinicians.”. Ann Med 46 (5). Ann Med: 283-9. doi:10.3109/07853890.2014.898863.
. 2014. “Treatment Of Older Patients With High-Risk Myelodysplastic Syndromes (Mds): The Emerging Role Of Allogeneic Hematopoietic Stem Cell Transplantation (Allo Hsct).”. Curr Hematol Malig Rep 9 (1). Curr Hematol Malig Rep: 57-65. doi:10.1007/s11899-013-0195-9.